Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-16. (Cancelled)

17. (Withdrawn) A method of treating a vascular proliferative disease in a patient comprising site specifically administering *in vivo* a therapeutically effective amount of a composition comprising a pharmaceutical carrier and a nucleic acid encoding p27, wherein said amount is sufficient for inhibiting proliferation of a vascular smooth muscle cell.

18. (Withdrawn) The method of claim 17, wherein the nucleic acid encodes a mutated p27 comprising one or more amino acid insertions, deletions or substitutions in native p27, wherein the mutated p27 has substantially the same biological function as native p27.

19. (Withdrawn) The method of claim 17, wherein the nucleic acid encodes native p27.

20. (Withdrawn) The method of claim 17, wherein the nucleic acid is an expression

vector.

21. (Withdrawn) The method of claim 17, wherein a viral particle contains the nucleic acid.

22. (Withdrawn) The method of claim 17, wherein a liposome contains the nucleic acid.

23. (Withdrawn) The method of claim 17, wherein the vascular proliferative disease is restenosis.

24. (Withdrawn) The method of claim 23, wherein the restenosis is coronary or peripheral.

25. (Withdrawn) The method of claim 17, wherein the vascular proliferative disease is atherosclerosis.

26. (Withdrawn) The method of claim 17, wherein the vascular proliferative disease is anglogenesis.

27. (Withdrawn) The method of claim 17, wherein a catheter is used to site specifically administer *in vivo* the therapeutically effective amount of the composition.

28. (Withdrawn) A method of inhibiting smooth muscle cell growth in a patient comprising site specifically administering *in vivo* a therapeutically effective amounts of a composition comprising a pharmaceutical carrier and a nucleic acid encoding p27, wherein said amount is sufficient for inhibiting growth of a smooth muscle cell.

29. (Currently amended) A ~~kit~~ combination for treating a vascular proliferative disease in a patient comprising a catheter and a nucleic acid comprising a gene encoding a single cyclin-dependent kinase inhibitor, wherein the cyclin-dependent kinase inhibitor is p27.

30. (Currently amended) The ~~kit~~ combination of claim 29, wherein the catheter is a single balloon catheter.

31. (Currently amended) The ~~kit~~ combination of claim 29, wherein the catheter is a double balloon catheter.

32. (Currently amended) The ~~kit~~ combination of claim 29, wherein the nucleic acid is an expression vector.

33. (Currently amended) The ~~kit~~ combination of claim 29, wherein a viral particle contains the nucleic acid.

34. (Currently amended) The ~~kit~~ combination of claim 29, further comprising a liposome.

35. (Cancelled)

36. (Currently amended) The ~~kit~~ combination of claim 29, wherein the nucleic acid further comprises a gene encoding a cytotoxic agent.

37. (Currently amended) The ~~kit~~ combination of claim 36, wherein the cytotoxic agent is selected from the group consisting of thymidine kinase, cytosine kinase, cytosine deaminase, and nitric oxide synthetase.

38. (Currently amended) The ~~kit~~ combination of claim 37, wherein cytotoxic agent is thymidine kinase.

39. (Currently amended) The ~~kit~~ combination of claim 36, wherein the gene encoding p27 and the gene encoding the cytotoxic agent are operatively linked.

40. (Currently amended) The ~~kit~~ combination of claim 39, wherein the gene encoding p27 and the gene encoding the cytotoxic agent are operatively linked such that they form a fusion protein.

41. (Currently amended) The ~~kit~~ combination of claim 40, wherein the fusion protein is a p27-thymidine kinase fusion protein.

42. (Currently amended) The ~~kit~~ combination of claim 36, wherein the gene encoding p27 and the gene encoding the cytotoxic agent form a dicistronic construct.